济南老年类风湿如何治疗(济南强制性脊柱炎的b27) (今日更新中)

WASHINGTON, June 7 (Xinhua) -- Advanced hepatitis C patients with chronic liver disease may benefit from drinking coffee during treatment, according to a new study published Tuesday in Gastroenterology, the official journal of the American Gastroenterological Association Institute.The study shows that patients who received peginterferon plus ribavirin treatment and who drank three or more cups of coffee per day were two times more likely to respond to treatment than non- drinkers.Among non-drinkers, 46 percent had an early virologic response; 26 percent had no detectable serum hepatitis C virus (HCV) ribonucleic acid at week 20; 22 percent had no detectable serum at week 48; and 11 percent had a sustained virologic response. In contrast, the corresponding proportions for those who drank three or more cups of coffee per day were 73 percent, 52 percent, 49 percent and 26 percent, respectively."Coffee intake has been associated with a lower level of liver enzymes, reduced progression of chronic liver disease and reduced incidence of liver cancer," said Neal Freedman, of the National Cancer Institute and lead author of this study. "Although we observed an independent association between coffee intake and virologic response to treatment, this association needs replication in other studies."Approximately 70 to 80 percent of individuals exposed to HCV become chronically infected. Worldwide, these individuals are estimated to number between 130 and 170 million. Higher coffee consumption has been associated with slower progression of pre- existing liver disease and lower risk of liver cancer. However, the relationship with response to anti-HCV treatment had not been previously evaluated.

LOS ANGELES, July 5 (Xinhua) -- NASA's Juno spacecraft is 30 days away before its first launch window opens, the Jet Propulsion Laboratory (JPL) announced on Tuesday."One month from today, our first launch window opens at 11:34 a. m. EDT (8:34 a.m. PDT) and lasts 69 minutes," said Jan Chodas, Juno project manager from NASA's JPL in Pasadena, Los Angeles."Our primary launch period is 22 days long, and so if weather or other issues come up on Aug. 5, we have 21 more days to get Juno flying. Once we get Juno into space, it's a five-year cruise to Jupiter.""The launch window is the length of time allotted every day for an attempt to launch the spacecraft," said Chodas. "The launch period is the period of time in days when everything is in the right place to get your mission off to the right start."For a mission like Juno, getting everything in the right place includes considering the size of the rocket and spacecraft, where our home planet -- and in particular Juno's launch pad -- is pointed at any moment, and its location in space relative to other celestial objects like Juno's final target, Jupiter.Juno is scheduled to launch aboard a United Launch Alliance Atlas V rocket from pad 41-C at the Cape Canaveral Air Force Station, Florida.The solar-powered spacecraft will orbit Jupiter's poles 33 times to find out more about the gas giant's origins, structure, atmosphere and magnetosphere and investigate the existence of a solid planetary core.JPL manages the Juno mission for the principal investigator, Scott Bolton, of Southwest Research Institute in San Antonio.The Juno mission is part of the New Frontiers Program managed at NASA's Marshall Space Flight Center in Huntsville, Alaska. Lockheed Martin Space Systems, Denver, built the spacecraft.

WASHINGTON, June 6 (Xinhua) -- Women who have higher levels of the appetite-controlling hormone leptin have fewer symptoms of depression, and this apparent inverse relationship is not related to body mass index (BMI), a new study finds. The results were presented Monday at The Endocrine Society's 93rd Annual Meeting in Boston, the United States."Animal data suggest that leptin may reduce anxiety and improve depression. Our study in women suggests that leptin may indeed have antidepressant qualities," said the study's lead author, Elizabeth Lawson, of Massachusetts General Hospital and Harvard Medical School in Boston.Leptin, the product of fat cells, signals satiety, or fullness. It is low in thin women and high in obese women, according to Lawson. She also said there is an increased prevalence of anxiety and depression in certain conditions in which leptin levels are typically low. These include the eating disorder anorexia nervosa, in which there is abnormally low weight and body fat, and functional hypothalamic amenorrhea, in which women have stopped menstruating despite having normal weight."It is unknown whether low leptin levels contribute to the development of mood disorders in these women," Lawson said.She and her co-workers studied the relationship between leptin levels and symptoms of anxiety and depression in 64 women. Fifteen of the women had anorexia nervosa, 12 were normal weight with hypothalamic amenorrhea, 20 were normal weight and in good health, and 17 were overweight or obese but still healthy.All subjects were asked questions to assess symptoms of depression and anxiety, with high scores indicating more symptoms. Besides measuring leptin levels in the blood, the researchers assessed the women's BMI, a measure of weight for height.The relationship between leptin and depression symptoms was independent of BMI. This finding indicates that leptin may mediate symptoms of depression and that this effect is not a function of low weight, Lawson said."Further research administering leptin to humans will be important in understanding whether this hormone has a potential role in the treatment of depression," she said.

RIO DE JANEIRO, Aug. 31 (Xinhua) -- The Brazilian city of Rio de Janeiroe may have an unprecedented dengue fever epidemic next summer, its mayor warned on Wednesday.The increasing number of dengue fever cases in the past few months shows similarities to the months predecing the 2002 and 2008 epidemics, Mayor Eduardo Paes said."Everything points to a new cycle of the disease, certainly the worst epidemic in Rio's history," he said.In 2008, Rio registered some 250,000 cases of dengue fever, with 174 people confirmed dead from the disease. In 2002, Rio had some 290,000 dengue fever cases and 91 people died.In efforts to halt the spread of the disease, Paes has declared a state of alert and is determined to take a series of measures to eliminate the habitat of the Aedes aegypti mosquito, which transmits dengue fever through its bite.Paes also announced an increase in the number of health care units for dengue fever patients. The total cost of a dengue prevention and combat program, which is expected to last until April 2012, will reach 42 million reais (26.25 million U.S. dollars).There is no vaccine against dengue fever, but Brazilian scientists are currently working on one which will immunize against four types of the disease.

WASHINGTON, June 21 (Xinhua) -- A new study from Harvard School of Public Health (HSPH) and University of California, San Francisco, researchers suggests that men with prostate cancer who smoke increase their risk of prostate cancer recurrence and of dying from the disease. The study will be published Wednesday in the Journal of the American Medical Association."In our study, we found similar results for both prostate cancer recurrence and prostate cancer mortality," said Stacey Kenfield, lead author and a research associate in the HSPH Department of Epidemiology. "These data taken together provide further support that smoking may increase risk of prostate cancer progression."Kenfield and her colleagues conducted a prospective observational study of 5,366 men diagnosed with prostate cancer between 1986 and 2006 in the Health Professionals Follow-Up Study. The researchers documented 1,630 deaths, 524 (32 percent) due to prostate cancer, 416 (26 percent) due to cardiovascular disease, and 878 prostate cancer recurrences.The researchers found that men with prostate cancer who were current smokers had a 61 percent increased risk of dying from prostate cancer, and a 61 percent higher risk of recurrence compared with men who never smoked. Smoking was associated with a more aggressive disease at diagnosis, defined as a higher clinical stage or Gleason grade (a measure of prostate cancer severity). However, among men with non-metastatic disease at diagnosis, current smokers had an 80 percent increased risk of dying from prostate cancer.Compared with current smokers, men with prostate cancer who had quit smoking for 10 or more years, or who had quit for less than 10 years but smoked less than 20 pack-years before diagnosis, had prostate cancer mortality risk similar to men who had never smoked. Men who had quit smoking for less than 10 years and had smoked 20 or more pack-years had risks similar to current smokers."These data are exciting because there are few known ways for a man to reduce his risk of dying from prostate cancer," said senior author Edward Giovannucci, professor of nutrition and epidemiology at HSPH. "For smokers, quitting can impact their risk of dying from prostate cancer. This is another reason to not smoke."Prostate cancer is the most frequently diagnosed form of cancer diagnosed in the United States and the second leading cause of cancer death among U.S. men, affecting one in six men during their lifetime. More than two million men in the U.S. and 16 million men worldwide are prostate cancer survivors.

来源：资阳报